Bevacizumab better than gold standard imaging at detecting tumors
Wednesday, October 22, 2008 - 11:07
in Health & Medicine
Scientists have developed a new imaging agent that can be used in scanning for tumours, and which gives a much clearer and more precise image than existing methods. The discovery has the potential to revolutionise pre-clinical cancer research and clinical diagnostic practice, and it makes use of compounds that have already been approved for treating patients: the anti-cancer drug bevacizumab (Avastin) and Copper-64, a radioactive copper nuclide, which is approved by the US Food and Drug Administration (FDA) for some clinical trials.
Read the whole article on Physorg
More from Physorg
Related
- Bevacizumab better than gold standard imaging at detecting tumorsWed, 22 Oct 2008, 8:22:19 EDT
- Project Zero Delay accelerates drug's path to clinical trialMon, 3 Aug 2009, 16:24:58 EDT
- New drug agent knocks out multiple enzymes in cancer pathwayWed, 25 Mar 2009, 14:46:40 EDT
- Patients will face delays in getting diagnostic scans due to severe shortage of imaging agentsFri, 5 Sep 2008, 19:28:56 EDT
- Research sheds light on workings of anti-cancer drugThu, 26 Nov 2009, 14:39:29 EST